Opdivo (nivolumab)

Mesothelioma Trial Involving UV1 Cancer Vaccine and Immunotherapy

A new mesothelioma clinical trial is taking place in Oslo, Norway. The trial is looking at the UV1 cancer vaccine alongside immunotherapy. The vaccine is a peptide-based drug that activates a T-cell response, allowing the immunotherapy drugs to work better. This will be the first time that UV1 is being[…]

Read More »

Opdivo and Yervoy Combination Could Lengthen Aggressive Mesothelioma Sufferers’ Lives

The combination of Yervoy and Opdivo was tested on mesothelioma and the overall survival was promising.   The overall survival was 18.1 months versus 14.1 months for patients receiving just chemotherapy. This is the first time that a phase III trial had an improved survival with an immunotherapy combination in a[…]

Read More »

Opdivo and Yervoy Work Together to Treat Pleural Mesothelioma

Mesothelioma is an aggressive cancer with very few treatment options. Patients have a low survival rate, but there is hope with clinical trials. If a clinical trial is found to be effective, patients could live longer and could eventually be cured. Opdivo and Yervoy are two immunotherapy drugs that are[…]

Read More »

Nivolumab to Help Treat Mesothelioma

A new study found that the PD-L1 inhibitor nivolumab is effective in mesothelioma. It was tested on patients and showed that it could be a safe and effective treatment for those whose first line treatments have failed. Nivolumab is an immunotherapy drug that helps the immune system fight cancer cells.[…]

Read More »

New Clinical Trial Testing Effectiveness of Immunotherapy and Chemotherapy Before Surgery

Mesothelioma, the cancer of the linings of different organs, but primarily the lungs, has a poor prognosis and survival rate for those who are diagnosed. Since there is no cure, treatments helping to extend people’s lives need to be tested. Clinical trials help doctors find new ways to treat mesothelioma[…]

Read More »

Opdivo and MTG201 Together Could Potentially Treat Mesothelioma

Typical cancer treatments are hard on the body and are not always effective. When treating someone for cancer, chemotherapy is typically used, which kills cancer cells or stops them from growing or spreading. Chemotherapy can also kill healthy cells, which makes it hard on the body. Immunotherapy is another option,[…]

Read More »

Less than Half of Cancer Patients Eligible for Immunotherapy Treatments

In late 2017, the FDA approved Keytruda (pembrolizumab) as an immunotherapy treatment for cancer.  It’s typically used to treat inoperable metastatic non-small cell lung cancer and melanoma but it has also been approved by the FDA to treat any unresectable or metastatic solid tumor, such as those found in mesothelioma.[…]

Read More »

Potential Breakthrough in Immunotherapy after Nivolumab Study Results

Immunotherapy treatments have once again made headlines, revolutionizing modern medicine and the way we have come to understand cancer treatment. The latest study results published in the American Journal of Case Reports, focuses on Opdivo (nivolumab), a type of check point inhibitor designed to stop immune cells from attacking the[…]

Read More »